Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20138624 | 0.91 | PRMT1 (0.50) | PRMT1ADRA1ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20725190 | 0.85 | ECE1 (0.45) | PRMT1ADRA1ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8995201 | 0.79 | PRMT1 (0.68) | PRMT1ADRA1ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4746485 | 0.78 | TDP1 (0.46) | MAPK1EPHX2EPHX1 | |
| SCHEMBL10045225 | 0.78 | CA3 (0.47) | PRMT1MAPK1EPHX1 | |
| SCHEMBL2804471 | 0.78 | PRMT1 (1.00) | PRMT1ADRA1AMAPK1LMNATSHR | |
| SCHEMBL6065930 | 0.78 | PRMT1 (0.74) | PRMT1ADRA1ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11127968 | 0.78 | PRMT1 (0.74) | PRMT1ADRA1ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17087514 | 0.78 | PRMT1 (0.74) | PRMT1ADRA1ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2808479 | 0.78 | PRMT1 (0.74) | PRMT1ADRA1ACYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856285-B2 | Reagents for universal site-specific labeling and modifications of nucleic acids | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-01-02 | — | — | US | disclosed |
| US-20160272669-A1 | NOVEL REAGENTS FOR UNIVERSAL SITE-SPECIFIC LABELING AND MODIFICATIONS OF NUCLEIC ACIDS | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2016-09-22 | — | — | US | disclosed |
| US-20160272669-A1 | NOVEL REAGENTS FOR UNIVERSAL SITE-SPECIFIC LABELING AND MODIFICATIONS OF NUCLEIC ACIDS | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2016-09-22 | — | — | US | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272669-A1 | NOVEL REAGENTS FOR UNIVERSAL SITE-SPECIFIC LABELING AND MODIFICATIONS OF NUCLEIC ACIDS | RNGTT, PNKP, ADAR | PRMT1 3038/4885ADRA1A 4734/4885CYP1A2 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.